Showing 1 - 10 of 20,290
Objective: To assess the short-term direct medical costs and effectiveness associated with achieving recommended glycaemic goals using commonly prescribed first-line oral antihyperglycaemic medications in type 2 diabetes mellitus. Materials and Methods: A literature-based, decision-tree model...
Persistent link: https://www.econbiz.de/10005590335
A short term (6-month) cost-effectiveness model has been developed to simulate current medical practice and disease progression in patients with type 2 (non-insulin-dependent) diabetes mellitus uncontrolled by diet and exercise. The model is based on decision-analytical techniques and includes...
Persistent link: https://www.econbiz.de/10005590470
Persistent link: https://www.econbiz.de/10005243165
Persistent link: https://www.econbiz.de/10004990365
Disease management programs have been implemented into the German healthcare system. According to recent legislation they must include structured treatment and teaching programs for patients with diabetes mellitus and/or hypertension. This paper provides an overview of the current situation in...
Persistent link: https://www.econbiz.de/10005448900
Bodyweight is an acknowledged independent risk factor for coronary heart disease (CHD). The present model analysis was undertaken to investigate the clinical and economic impact of bodyweight gain in patients with type 2 (non-insulin-dependent) diabetes mellitus and its effects on the...
Persistent link: https://www.econbiz.de/10005590380
This willingness-to-pay (WTP) analysis is the first study of its kind undertaken in Australia to support an application for listing of a new drug on the Australian national formulary. The technique offers the advantage of being able to summarise diverse outcomes of therapy in a single unit of...
Persistent link: https://www.econbiz.de/10005590425
Objective: The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. Design: The World Health...
Persistent link: https://www.econbiz.de/10005590448
Persistent link: https://www.econbiz.de/10005590469
Persistent link: https://www.econbiz.de/10005590549